Veracyte/$VCYT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Veracyte
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
Ticker
$VCYT
Sector
Primary listing
Employees
755
Headquarters
Website
Veracyte Metrics
BasicAdvanced
$3.7bn
33.22
$1.39
1.93
-
Price and volume
Market cap
$3.7bn
Beta
1.93
52-week high
$60.91
52-week low
$22.92
Average daily volume
1.4m
Financial strength
Current ratio
9.162
Quick ratio
8.598
Long term debt to equity
2.473
Total debt to equity
2.889
Interest coverage (TTM)
89,359.00%
Profitability
EBITDA (TTM)
110.191
Gross margin (TTM)
73.65%
Net profit margin (TTM)
20.37%
Operating margin (TTM)
15.90%
Effective tax rate (TTM)
1.32%
Revenue per employee (TTM)
$740,000
Management effectiveness
Return on assets (TTM)
3.95%
Return on equity (TTM)
8.77%
Valuation
Price to earnings (TTM)
33.22
Price to revenue (TTM)
6.542
Price to book
2.66
Price to tangible book (TTM)
6.86
Price to free cash flow (TTM)
22.145
Free cash flow yield (TTM)
4.52%
Free cash flow per share (TTM)
2.092
Growth
Revenue change (TTM)
17.28%
Earnings per share change (TTM)
313.15%
3-year revenue growth (CAGR)
19.58%
10-year revenue growth (CAGR)
26.25%
3-year earnings per share growth (CAGR)
51.07%
10-year earnings per share growth (CAGR)
0.11%
What the Analysts think about Veracyte
Analyst ratings (Buy, Hold, Sell) for Veracyte stock.
Veracyte Financial Performance
Revenues and expenses
Veracyte Earnings Performance
Company profitability
Veracyte News
AllArticlesVideos
Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026
Business Wire·3 weeks ago
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
Business Wire·2 months ago
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.